NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE111935 Query DataSets for GSE111935
Status Public on Jul 02, 2019
Title Investigation of target molecule alterations by a cDNA microarray in ATO-treated HCC cells
Organism Homo sapiens
Experiment type Expression profiling by array
Summary BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) has a high mortality rate due to the lack of effective treatments and drugs. Arsenic trioxide (As2O3, ATO, arsenious acid), which has been proved to successfully treat acute promyelocytic leukemia (APL), was recently reported to show therapeutic potential in solid tumors including liver cancer. Although the mechanistic effects of ATO in APL are established, its anticancer mechanism of action in HCC is still unclear. METHODS: We established an HCC subcutaneous xenograft and intrahepatic metastasis mouse model. In CSC models, tumorspheres and the flow cytometry analysis of CSC markers together with limiting dilution and serial transplantation were used. We compared mRNA expression profiles of the ATO-treated and control cells with mRNA microarray. The expression of target molecule or a clinical correlation was analyzed by immunohistochemistry staining in tissues from ATO-treated mouse and 76 HCC patients. We generated five stable minichromosome maintenance protein 7 (MCM7)-knockdown and two stable MCM7-overexpression HCC cell lines. The chromatin immunoprecipitation (ChIP) assays, immunoprecipitation (IP) assays, the dual luciferase reporter assays, a green biarsenical labeling reagent (FlAsH-EDT2) and a “competing endogenous RNA” (ceRNA) analysis were used.

RESULTS: ATO could inhibit the liver tumor-initiating capacity and distant metastasis and prolongs survival in mice. We then screened and found that ATO downregulates the overexpression of MCM7 which is correlated with the progression and prognosis in HCC patients. Knockdown of MCM7 expression recapitulates the inhibition function of ATO on self-renewal of cancer stem cells (CSCs), while overexpression of MCM7 abolishes the inhibition function of ATO on tumorsphere formation. Most importantly, we revealed that ATO directly binds to the MCM7 protein and disturbs the interaction between serum response factor (SRF) and MCM7, resulting in downregulation of MCM7 transcription. A ceRNA analysis also indicated the alterations of endogenous MCM7-associated gene networks involved in stemness-related signaling pathways and cell differentiation.

CONCLUSIONS: Here, for the first time, we report that ATO inhibits liver CSCs through blocking the interaction between SRF/MCM7 and suppressing MCM7 autoregulation activity.
 
Overall design The profiles of differentially expressed mRNAs were analyzed in SMMC-7721 cells and Huh7.5.1 cells treated with 3.6 μM arsenic trioxide (48 hours) or PBS as controls.
 
Contributor(s) Zhou J, Wang H, Zhang B, Yue W, Pei X
Citation(s) 31186405
Submission date Mar 16, 2018
Last update date Jul 02, 2019
Contact name Jun-Nian Zhou
E-mail(s) hcoohboy@163.com
Organization name Institute of Health Service and Transfusion Medicine
Lab Stem Cell and Regenerative Medicine
Street address 27# Taiping Road
City Beijing
ZIP/Postal code 100850
Country China
 
Platforms (1)
GPL15207 [PrimeView] Affymetrix Human Gene Expression Array
Samples (8)
GSM3045430 SMMC-7721 HCC cells_arsenic trioxide treated (48h), biological rep1
GSM3045431 SMMC-7721 HCC cells_PBS treated (48h), biological rep1
GSM3045432 SMMC-7721 HCC cells_arsenic trioxide treated (48h), biological rep2
Relations
BioProject PRJNA438604

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE111935_RAW.tar 16.2 Mb (http)(custom) TAR (of CEL)
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap